Thyroid Cancer: FDG Imaging & the RAI/FDG Flip-Flop

Quick Answer

In differentiated thyroid cancer (DTC), iodine avidity and FDG avidity move in opposite directions as the tumor dedifferentiates — the flip-flop phenomenon. Well-differentiated, iodine-avid disease concentrates radioiodine and is treatable with ¹³¹I; as the tumor loses differentiation it stops taking up iodine and becomes FDG-avid. This is why FDG-PET is the test of choice in the "TENIS" scenario — a rising Thyroglobulin with a Negative Iodine Scan — and why FDG positivity carries adverse prognostic weight. The two tracers are complementary, and their discordance is the imaging signature of aggressive, radioiodine-refractory disease.

The flip-flop, and why it happens

Radioiodine uptake depends on the sodium-iodide symporter (NIS) and preserved thyroid differentiation; FDG uptake tracks glycolytic, proliferative burden. As DTC dedifferentiates, NIS expression falls (loss of iodine avidity) while glucose metabolism rises (gain of FDG avidity). So a lesion is typically either iodine-avid or FDG-avid, rarely both — the flip-flop. This is the thyroid instance of the general theranostic rule that a target-directed therapy (here ¹³¹I) can only treat what still expresses the target.

The high-yield clinical scenarios

What the boards and the clinic test:

• TENIS (Thyroglobulin-Elevated, Negative Iodine Scan): rising thyroglobulin (or rising anti-Tg antibodies) with a negative diagnostic radioiodine scan → FDG-PET/CT to localize the recurrent/metastatic disease. This is the flagship indication.
• Prognosis: FDG-avid disease is more aggressive and predicts poorer response to ¹³¹I and worse survival — high FDG volume is a strong negative prognostic marker.
• Radioiodine-refractory disease: defined clinically (no/loss of uptake, progression despite uptake, or progression after adequate cumulative activity) — these patients are candidates for systemic therapy (e.g. multikinase or selective inhibitors) rather than more ¹³¹I.
• TSH stimulation (thyroid-hormone withdrawal or recombinant TSH) can modestly increase FDG detection, though FDG is often performed without it.

Redifferentiation strategies (e.g. MEK/BRAF inhibitors) can restore NIS expression and iodine avidity in selected RAI-refractory tumors, temporarily "flipping" a lesion back toward iodine-treatable — a modern extension of the flip-flop concept and an active area.

Complementary, not competing

FDG and radioiodine imaging answer different questions and are used together across the disease course: radioiodine scanning (and post-therapy scans) for iodine-avid, treatable disease; FDG-PET for the dedifferentiated, iodine-negative, thyroglobulin-positive disease that radioiodine will miss. Anaplastic and poorly differentiated thyroid cancers are FDG-avid and non-iodine-avid from the outset.

Common Pitfalls / Cautions

• A negative radioiodine scan does not mean no disease — with elevated thyroglobulin it means iodine-negative disease; image with FDG.
• Physiologic/benign neck uptake and inflammatory nodes can mimic disease on FDG — correlate with anatomy and thyroglobulin trend.
• Do not offer further ¹³¹I to clearly radioiodine-refractory, FDG-avid disease expecting benefit.

Board Pearls

• The inverse relationship operates at the lesion level — a single patient can harbor both iodine-avid and FDG-avid metastases, so read the post-therapy radioiodine scan and FDG-PET together to map the whole disease burden.
• Hürthle-cell (oncocytic) and poorly differentiated carcinomas are typically iodine-poor and FDG-avid at presentation — FDG is the functional test of choice rather than diagnostic radioiodine.
• FDG-PET yield rises with higher serum thyroglobulin and more aggressive histology; a modestly elevated thyroglobulin may still give a negative FDG scan.
• Medullary and anaplastic carcinomas do not concentrate radioiodine; anaplastic thyroid cancer is intensely and uniformly FDG-avid.

Differential Diagnosis

• Iodine-avid, FDG-negative disease — well-differentiated (classically micronodular pulmonary metastases); still radioiodine-treatable.
• FDG-avid, iodine-negative disease — dedifferentiated, radioiodine-refractory (the flip-flop endpoint).
• FDG-avid and iodine-avid in the same lesion — uncommon mixed/transitional differentiation.
• FDG-positive but benign — reactive/inflammatory cervical nodes, thyroid-remnant or post-RAI inflammation, muscle, and brown fat.
• Thyroglobulin elevated with both scans negative — microscopic/small-volume disease below resolution, or anti-thyroglobulin antibody interference affecting the assay.

Reporting Checklist

• State the thyroglobulin (and anti-Tg antibody) level and trend, whether TSH-stimulated or suppressed, and the prior ¹³¹I history.
• Correlate with the most recent diagnostic or post-therapy radioiodine scan and explicitly describe lesions as concordant vs discordant.
• Report the number, SUV, and volume of FDG-avid lesions given their prognostic weight.
• Distinguish physiologic/benign uptake from disease.
• Give a management-relevant impression — iodine-avid (RAI candidate) vs FDG-avid, radioiodine-refractory (systemic therapy; consider redifferentiation).

Self-Check

Key References

• ATA differentiated thyroid cancer guidelines — radioiodine-refractory definitions and the role of FDG-PET in thyroglobulin-positive, iodine-negative disease.
• Studies of FDG-PET prognosis in DTC and of redifferentiation (MEK/BRAF inhibition) restoring radioiodine avidity.